In 2020, during the COVID-19 pandemic lockdown, DiagnoSearch conducted a large-scale clinical trial within 4 weeks of protocol finalization. The study recruited over 6,000 high-risk, healthy volunteers across 40 sites. Traditional processes such as paper-based informed consent forms, patient diaries, and manual site monitoring were challenging due to infection risks and operational delays. Further, deploying suitable critical trial infrastructure including eConsent, eCRF, IWRS, pharmacovigilance, and remote monitoring systems were difficult, as they typically take 8–10 weeks to implement. The study required a full-spectrum clinical trial service, with minimal in-person interaction and no compromise on data integrity, safety, or compliance.
DiagnoSearch deployed its Wide-Angle-Insights™ Platform, a comprehensive, modular, AI-powered solution, within days. This end-to-end platform supported
Rapid remote consenting through a secure, multi-language mobile app
Electronic patient-reported outcomes (ePRO/eCOA) to reduce on-site visits and improve subject convenience
Mobile notifications for real-time engagement and data entry prompts
A unified pharmacovigilance database, allowing SAE data entry once, with no need for reconciliation
Real-time medical review that enabled fast signal detection and resolution
An inbuilt risk engine for proactive issue identification and mitigation
Live dashboards for centralized oversight and timely course corrections
Due to DiagnoSearch’s tech-driven approach, the trial was able to
COVID-19 Vaccine Trial Executed During Lockdown
During the COVID-19 pandemic, DiagnoSearch executed a large-scale vaccine trial using its AI-powered Wide-Angle-Insights™ platform. From eConsent to real-time monitoring, the entire study was digitally completed in under 2 months, ensuring speed, safety, and data quality with zero compromise.
